Pular para o conteúdo
Menu
Mix Vale

Samsung Bioepis develops high-dose SC technology to expand biosimilars

Beatriz
Por 2 min de leitura
Compartilhe
Edifício da Samsung Bioepis em Songdo - Reprodução/Samsung Bioepis
Foto: Edifício da Samsung Bioepis em Songdo - Reprodução/Samsung Bioepis

Samsung Bioepis, a company affiliated with Samsung Epice Holdings, has secured mastery of a new technology capable of changing intravenous to subcutaneous (SC) formulations. The innovation is based on recombinant human hyaluronidase (PH20) and could allow the company to expand its presence in the biosimilars market, in a scenario where large pharmaceutical companies seek to convert popular medicines for SC application, intensifying the competition for patents.

Publicidade

Internal tests of the SC modification technology, using the PH20, were completed by Samsung Bioepis, according to data released by the biotechnology industry. The company achieved significant progress by developing its own methods for cultivation and purification, in addition to producing its own hyaluronidase. This approach distinguishes Samsung Bioepis from competitors such as Halozyme in the United States and Alteogen in Korea, and is seen as a crucial strategy for avoiding intellectual property litigation, given that both the substance and the processes are subject to patents.

The ability to convert medications from intravenous (IV) to subcutaneous (SC) formulations, especially those based on antibodies in high doses, fundamentally depends on the technology that employs PH20. In previous cases, such as Benepali SC (derived from Enbrel) and Imraldi SC (derived from Humira), Samsung Bioepis was able to develop SC versions with simple adjustments, as they were drugs with a low dose of antibodies. However, new and more effective cancer drugs, which often have high doses, require the use of PH20-based technology, which temporarily acts on the subcutaneous tissue barrier to allow absorption.

Publicidade

The expectation is that Samsung Bioepis will apply this innovation to high-impact medicines, such as Keytruda, the most sold cancer drug in the world, developed by Merck (MSD) and currently in the development phase as a biosimilar. Another potential target is Enhertu, a leading antibody-drug conjugate (ADC) from Japanese company Daiichi Sankyo. A spokesperson for Samsung Bioepis, however, stated that “nothing has been officially decided on which medicines the technology will be used in.”

Publicidade

Beatriz Lima é colaboradora da redação do Mix Vale, portal de notícias com cobertura de Brasil e mundo. Produz conteúdo nas editorias de economia e benefícios, com foco em informação de serviço para o leitor brasileiro. Escreve para o portal desde 2024.

Notícias relacionadas

Mais lidas

  1. Ciência

    Meteoro no Nordeste: bólido cruza o céu de cinco estados às 21h34 e mobiliza buscas por fragmentos na Paraíba

  2. Caixa Econômica Federal

    Pé-de-Meia paga parcela de R$ 1.000,00 a aprovados no ensino médio de 2026 entre fevereiro e março de 2027

  3. Política

    Com obstrução parcial no intestino, Jair Bolsonaro é internado no hospital DF Star em Brasília

  4. INSS

    Recuperação da senha Gov.br pelo celular exige reconhecimento facial ou código por SMS para o Meu INSS

  5. EUA

    Terremoto em Los Angeles atinge magnitude 4,2 e causa tremores leves em Commerce na madrugada

  6. Matéria Publicitária

    MineMV é o novo jogo grátis de construir com blocos; veja como jogar e liberado para todas as idades

  7. Política

    Regulamentação da escala 5×2 pelo governo encarece cálculo da hora extra a partir de 16 de dezembro

  8. Santa Catarina

    Acidente de trânsito na SC-108 envolve carro e moto e deixa motociclista morto em São Ludgero

  9. Mundo

    Jornalista italiano Corrado Augias morre aos 91 anos; presidente da Itália lamenta a perda

  10. Loterias

    Rendimento de R$ 40 milhões da Mega-Sena 3088 chega a R$ 337 mil por mês no Tesouro Direto